375 20 Pill — YELLOW OVAL, 17mm — Naproxen

Imprint	375 / 20
Colour	YELLOW
Shape	OVAL
Size	17
Strength	NAPROXEN 375 mg;ESOMEPRAZOLE MAGNESIUM 20 mg
Dosage form	Tablet, Delayed Release
Manufacturer	AstraZeneca LP
NDC	0186-0510
Schedule	—
Availability	—
Ingredients	NAPROXEN[NAPROXEN];ESOMEPRAZOLE MAGNESIUM[ESOMEPRAZOLE]

What does this imprint mean?

The imprint "375 20" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Naproxen

Uses and warnings

BOXED WARNING: Boxed Warning - Cardiovascular & GI Risk: NSAIDs increase risk of serious cardiovascular thrombotic events (myocardial infarction, stroke) that can be fatal, potentially early in treatment. They also cause increased risk of serious gastrointestinal bleeding, ulceration, and perforation, which can occur without warning symptoms. Key Warnings Include: - Contraindicated after coronary artery bypass graft surgery - "Patients with a prior history of peptic ulcer disease...had a greater than 10-fold increased risk for developing a GI bleed" - Risk of hepatotoxicity, hypertension, heart failure, renal toxicity, anaphylactic reactions, serious skin reactions, and hematologic toxicity - Avoid in pregnant women starting at 30 weeks gestation due to fetal ductus arteriosus closure risk

Naproxen sodium tablets treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and juvenile arthritis. They also relieve tendonitis, bursitis, acute gout, pain, and primary dysmenorrhea. "Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals."

Read the full drug profile →